Entity

Time filter

Source Type


Ness T.,Universitats Augenklinik Freiburg | Paulus W.,Institute For Reproduktionstoxikologie
Ophthalmologe | Year: 2012

Ocular therapy is necessary even during pregnancy but the use of pharmaceutical substances bears the risk of side effects on mother and child. The article reflects current knowledge on how to treat the most important eye diseases during pregnancy and breastfeeding. The review covers the diagnostics (tonometry, mydriasis, angiography) as well as treatment of infections of the eyes, glaucoma, allergies, diabetic retinopathy, pain and inflammation. © 2012 Springer-Verlag. Source


Ness T.,Universitats Augenklinik Freiburg | Paulus W.,Institute For Reproduktionstoxikologie Ravensburg
Ophthalmologe | Year: 2010

Pregnancy may cause ocular changes, for example refractive changes or contact lens intolerance. A number of ocular diseases may deteriorate. Especially preexisting diabetic retinopathy may worsen. Vaginal delivery is nearly always possible. Caesarean section is not required due to myopia, peripheral retinal degenerations or after retinal surgery. Most topically applied drugs usually used in ophthalmology are safe during pregnancy. © 2010 Springer-Verlag. Source


Lang G.E.,Universitatsklinikum Ulm | Lang S.J.,Universitats Augenklinik Freiburg
Ophthalmologe | Year: 2011

Hematological diseases can lead to ocular manifestations in up to 90% of patients and sometimes the ophthalmological findings are the presenting symptom of the disease. The ocular manifestation is often asymptomatic. The diagnosis can be difficult especially when the ocular manifestation represents the first symptoms. In most cases the conjunctiva and retina are involved and are particularly found in patients with anemia, leukemia, Hodgkin and non-Hodgkin lymphoma, myeloproliferative and myelodysplastic syndromes and coagulopathies. Even opportunistic infections in cases of hematological diseases can lead to ocular manifestations. For unexplained retinal alterations with hemorrhage and cotton-wool spots an underlying hematological disease should be excluded. © 2011 Springer-Verlag. Source


Poloschek C.M.,Universitats Augenklinik Freiburg | Jagle H.,Universitats Augenklinik Regensburg
Ophthalmologe | Year: 2012

This article reviews the current pharmacological strategies to treat inherited retinal degeneration. To date there is no causal therapy despite growing knowledge of the particular pathomechanisms. However, treatment is available for complications, such as cystic macular changes and cystoid macular edema. To reduce retinal thickness systemic or topical carboanhydrase inhibitors can be applied and in rare cases combined with steroids when indicated, however reduction of retinal thickness is not always accompanied by improvement of visual acuity. Regular follow-up with optical coherence tomography is required. In some cases, potentially neuroprotective agents (valproic acid, ciliary neurotrophic factor and Ca2+ channel inhibitors) or food supplementation (vitamin A, lutein, synthetic retinoids and decosahexaenoic acid) may have a positive impact on disease progression (e. g. reduction in progression of visual field loss or individual electrophysiological parameters). However, beneficial effects and side effects, e. g. of vitamin A substitution, depend not only on the disease phenotype (such as retinitis pigmentosa) but also on the actual genotype. Furthermore, no data are available regarding the application of pharmaceuticals in the pediatric population. © 2012 Springer-Verlag. Source


Ness T.,Universitats Augenklinik Freiburg
Ophthalmologe | Year: 2010

Multidrug-resistant bacteria have emerged as an increasing threat in many areas of medicine. The most prominent multidrug-resistant pathogens are methicillin-resistant S. aureus (MRSA), vancomycin-resistant MRSA (VMRSA), vancomycin-resistant enterococci (VRE), and Enterobacteriaceae with extended-spectrum beta-lactamase (ESBL). In particular, MRSA and VRE cause infections seen in ophthalmology. The lids, lacrimal duct, and ocular surface are frequently involved. © 2010 Springer-Verlag. Source

Discover hidden collaborations